Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Related Experiment Videos

Hirudin in renal insufficiency.

Karl-Georg Fischer1

  • 1University Hospital Freiburg, Department of Medicine, Division of Nephrology and General Medicine, Germany. fischer@med1.ukl.uni-freiburg.de

Seminars in Thrombosis and Hemostasis
|November 7, 2002
PubMed
Summary

Recombinant hirudins require dose adjustments in patients with kidney disease due to impaired clearance. Close monitoring of drug levels is essential to prevent complications from altered pharmacokinetics.

Related Concept Videos

You might also read

Related Articles

Articles linked to this work by shared authors, journal, and citation graph.

Sort by
Same author

Mechanism and Clinical Presentation of Heparin-Induced Thrombocytopenia.

Hemodialysis international. International Symposium on Home Hemodialysis·2017
Same author

Successful immunoadsorption of life-threatening bleeding in factor VIII inhibitor disease, but no long-term remission with anti-CD20 treatment.

BMJ case reports·2015
Same author

Pulmonary infiltrate and painful nodular leg lesions in a patient with membranous glomerulonephritis.

BMJ case reports·2015
Same author

Reversible pulmonary hypertension in a kidney transplant with patent A-V fistula.

Clinical kidney journal·2015
Same author

Shared decision-making in antihypertensive therapy: a cluster randomised controlled trial.

BMC family practice·2013
Same author

Implementation of shared decision making by physician training to optimise hypertension treatment. Study protocol of a cluster-RCT.

BMC cardiovascular disorders·2012

Area of Science:

  • Pharmacology
  • Nephrology
  • Hematology

Background:

  • Recombinant hirudins (r-hirudins) are direct thrombin inhibitors used for anticoagulation, particularly in heparin-induced thrombocytopenia.
  • R-hirudins are primarily eliminated by the kidneys, leading to altered pharmacokinetics in patients with renal insufficiency.

Purpose of the Study:

  • To review the impact of renal impairment on r-hirudin pharmacokinetics.
  • To discuss strategies for safe and effective anticoagulation with r-hirudins in patients with kidney disease.

Main Methods:

  • Review of existing literature on r-hirudin pharmacokinetics and clinical use in renal impairment.
  • Analysis of monitoring techniques and dose adjustment strategies.
  • Evaluation of anticoagulation management during renal replacement therapy.

Main Results:

  • Renal insufficiency significantly reduces r-hirudin clearance, increasing half-life and AUC.
  • Dose reduction and close monitoring using ecarin clotting times (ECT) or chromogenic assays are necessary.
  • R-hirudin anticoagulation is feasible with renal replacement therapy if dosing and monitoring are optimized.
  • High-volume hemofiltration can reduce r-hirudin levels in cases of overdose or bleeding.

Conclusions:

  • Dosing of r-hirudins must be adjusted based on renal function to prevent accumulation and adverse events.
  • Effective anticoagulation with r-hirudins is achievable in renal failure with appropriate management.
  • Argatroban, a hepatically eliminated alternative, may be suitable for patients with renal insufficiency.

Related Experiment Videos